載入...
Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
Recent studies have indicated that afatinib is beneficial for patients with non‐small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations, while the effectiveness of afatinib rechallenge has not been fully defined. Here, we report a long‐term survival case o...
Na minha lista:
| 發表在: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley & Sons Australia, Ltd
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7396375/ https://ncbi.nlm.nih.gov/pubmed/32529804 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13532 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|